Atomic AI Announces Appointments of New Independent Member to its Board of Directors and Additions to the Scientific Advisory Board
Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, today announced the appointment of Stuart Peltz, Ph.D. as an independent board member to the Atomic AI Board of Directors, and the additions of Percy Carter, MBA, Ph.D., and Nicholas Meanwell, Ph.D. to their Scientific Advisory Board (SAB).
- Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, today announced the appointment of Stuart Peltz, Ph.D. as an independent board member to the Atomic AI Board of Directors, and the additions of Percy Carter, MBA, Ph.D., and Nicholas Meanwell, Ph.D. to their Scientific Advisory Board (SAB).
- “We are extremely pleased to have these highly regarded, experienced biotech leaders join in our efforts and believe in our mission,” said Raphael Townshend, Ph.D., Founder and CEO of Atomic AI.
- Peltz’s experience will help shape our strategy as we endeavor to streamline the discovery and development of novel therapies.
- “They have demonstrated tremendous progress integrating deep learning foundation models with experimental results to be able to predict and optimize RNA structures to enable rational drug design.